Herantis Pharma Plc.

Herantis Pharma Plc. is a clinical-stage biotechnology company focused on developing disease-modifying therapies for Parkinson’s disease. The company's lead product, HER-096, is an advanced small synthetic chemical peptidomimetic molecule designed based on the active site of the CDNF protein. It offers the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. Notably, a Phase 1a clinical trial has demonstrated promising safety and tolerability profiles, as well as efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. Founded in 2008 and headquartered in Finland, Herantis Pharma Plc. has its shares listed on the Nasdaq First North Growth Market Finland.

The most recent investment in Herantis Pharma Plc. was a Post-IPO Equity investment on December 19, 2022. Notably, the investor involved in this latest investment round was The European Innovation Council, signifying a vote of confidence from a prominent financial entity within the biotechnology and pharmaceutical industries. The company's dedication to addressing a significant unmet medical need within the Parkinson's disease space makes it an intriguing prospect for potential venture capital consideration.